Magali Haas attended Penn to receive her bachelor’s degree in Bioengineering before pursuing her doctorate degrees in Medicine and Neuroscience. After spending twelve years conducting neuroscience research and development at Johnson & Johnson, Magali founded and is now the CEO and President of Cohen Veterans Bioscience Inc. Her non-profit research organization is dedicated to fast-tracking diagnostics and therapeutics to advance brain health through cutting-edge research. Through the generosity and support of Steven A. Cohen, Cohen Veterans Bioscience launched targeted translational research initiatives in Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury (TBI) with a special focus on improving the detection and treatment of these conditions and related co-morbidities, so the burden may be lessened on service members, veterans, and their families. To ensure the future holds improved care for all individuals with brain disease, CVB assembles high-dimensional biomarker, biosensor, and phenotypic data to build computational predictive models of disease to enable an understanding of the biological mechanisms of disease that will accelerate the time to next generation diagnostics and treatments.
